Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Puma Biotechnology, Inc.
Information provided by (Responsible Party):
Puma Biotechnology, Inc. Identifier:
First received: September 26, 2013
Last updated: September 29, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)